DRUG DETERMINATION POLICY

Title: DDP-53 Plasminogen Deficiency: Ryplazim

Effective Date: 05/06/2022

Physicians Health Plan
PHP Insurance Company
PHP Service Company

Important Information - Please Read Before Using This Policy

The following policy applies to health benefit plans administered by PHP and may not be covered by all PHP plans. Please refer to the member's benefit document for specific coverage information. If there is a difference between this general information and the member's benefit document, the member's benefit document will be used to determine coverage. For example, a member's benefit document may contain a specific exclusion related to a topic addressed in a coverage policy.

Benefit determinations for individual requests require consideration of:

1. The terms of the applicable benefit document in effect on the date of service.
2. Any applicable laws and regulations.
3. Any relevant collateral source materials including coverage policies.
4. The specific facts of the particular situation.

Contact PHP Customer Service to discuss plan benefits more specifically.

1.0 Policy:

This policy describes the determination process for coverage of specific drugs.

This policy does not guarantee or approve benefits. Coverage depends on the specific benefit plan. Drug Determination Policies are not recommendations for treatment and should not be used as treatment guidelines.

2.0 Background or Purpose:

Ryplazim is a specialty drug indicated for the treatment of Plasminogen Deficiency type I by reducing pseudo-membrane lesions in the conjunctiva of the eyes, respiratory and central nervous system. These criteria were developed and implemented to ensure appropriate use for the intended diagnosis, if possible.

3.0 Clinical Determination Guidelines:

Document the following with chart notes:

I. Ryplazim intravenous (human plasminogen IV) [must meet all listed below]

A. Age: all ages

B. Prescriber: Ophthalmologist, Hematology/Oncology

C. Diagnosis and severity

1. Clinical features [must meet at least one listed below]

a. Pseudo-membrane formation in various organ systems

b. Impaired wound healing

c. First degree relative with plasminogen deficiency

2. Laboratory and genetic testing [must meet both listed below]

a. Plasminogen activity: activity level below 45 percent (normal range 75 to 120 percent)

b. Genetic testing: biallelic pathogenic variants in plasminogen

D. Other therapies: Only for patients that do not have access to plasminogen concentrate (eg. plasma, estrogen, immunosuppression)

E. Dosage regimen: Ryplazim intravenous (human plasminogen IV)

initial Dose				
Plasminogen activity level from baseline*	Dose (mg/Kg)	Frequency (days)	Duration (weeks)	Assessment (lesions improved)
< 10% increase	6.6	2	12	No: Continue until improvement
≥10% to ≤ 20% increase		3		No: dosing to every 2 days
>20% increase		4		No: dosing frequency increased at 1-day increments every 4-8 weeks
Maintenance Dose (after 12 weeks of initial dosing)				
Trough plasminogen activity level from baseline	Dose (mg/Kg)	Frequency (days)	Duration	Assessment (lesions resolved)
Not needed	6.6	2 to 4	ongoing	Yes: monitor lesions every 12 weeks
≥10% increase				No; consider other treatment options
<10% increase				No: redraw trough to confirm and consider discontinuing

**Draw Plasminogen activity level 72 hours after initial dose*

F. Approval

1. Initial: three months

2. Reapproval: three to six months depending on maintenance dose assessment

4.0 Coding:

CODES AFFECTED				
Code	**Brand**	**Generic**	**Billing (1u)**	**Prior Approval Required**
	Ryplazim	Human plasminogen		Yes

5.0 References, Citations & Resources:

1. Lexi comp Online® Lexi-Drugs®, Hudson, Ohio: Lexi-Comp, Inc.; Ryplazim accessed February 2022.
2. UpToDate Plasminogen deficiency https://www.uptodate.com/contents/plasminogen-deficiency?search=plasminogen%20deficiency&source=search_result&selectedTitle=1~27&usage_type=default&display_rank=1 accessed February 2022

6.0 Appendices:

7.0 Revision History:

Original Effective Date: 05/06/2022

Next Review Date: 05/06/2024

Revision Date	Reason for Revision
03/02/2022	Annual review, clarified policy instructions and formatting changes

Appendix I: Patient Safety and Monitoring

Drug	Adverse Reactions	Monitoring	REMS
Ryplazim intravenous human plasminogen IV	• Gastrointestinal: Abdominal pain, bloating, constipation, gastric dilation, nausea, xerostomia • Hematologic & oncologic: Hemorrhage • Immunologic: Antibody development • Nervous system: Dizziness, fatigue, headache • Neuromuscular & skeletal: Arthralgia, back pain, limb pain	• Labs: Plasminogen activity level at baseline, 72 hours after initial dose and as clinically indicated. • Hematology/oncology: if coagulation disorder monitor for bleeding • Respiratory: if airway disease monitor for obstruction or hemoptysis	None